Page last updated: 2024-08-23

pimonidazole and mk 2206

pimonidazole has been researched along with mk 2206 in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bussink, J; Grénman, R; Iida, M; Kaanders, JH; Span, PN; Stegeman, H; van der Kogel, AJ; Verheijen, MM; Waaijer, SJ; Wheeler, DL1

Other Studies

1 other study(ies) available for pimonidazole and mk 2206

ArticleYear
Activation of AKT by hypoxia: a potential target for hypoxic tumors of the head and neck.
    BMC cancer, 2012, Oct-10, Volume: 12

    Topics: Animals; Blotting, Western; Carcinoma, Squamous Cell; Cell Hypoxia; Cell Line, Tumor; Cell Survival; Combined Modality Therapy; ErbB Receptors; Fluorescent Antibody Technique; Head and Neck Neoplasms; Heterocyclic Compounds, 3-Ring; Humans; Hypoxia; Mice; Mice, Inbred BALB C; Mice, Nude; Nitroimidazoles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Radiation-Sensitizing Agents; Radiotherapy; Receptor, ErbB-2; Signal Transduction; Tumor Microenvironment; Xenograft Model Antitumor Assays

2012